AveXis
Founded Year
2012Stage
Acq - P2P | AcquiredTotal Raised
$75MValuation
$0000About AveXis
AveXis is a clinical-stage gene therapy company developing treatments for rare and life-threatening neurological genetic diseases. The company's initial product candidate, scAAV9.CB.SMN, is in an ongoing Phase 1 clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, an autosomal-recessive genetic disorder characterized by lower motor neuron loss and progressive muscle weakness. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for the survival of motor neurons. SMA Type 1 is the most common cause of infant mortality and is the second-most common autosomal recessive genetic disorder.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Latest AveXis News
Sep 12, 2023
News Provided By Share This Article Arowor Corp. tentative business development schemes Arowor Corp. pre-clinical pipeline Aron Workman's foundations and election, a microacquisition takeover spree, and project planning and development filled the first three quarters of 2023 We are expeditiously developing our applied sciences property, especially our computational suites and pharmaceutical candidates.” — Aron Workman, CEO LONDON, UNITED KINGDOM, September 12, 2023/ EINPresswire.com / -- Arowor Corp. (Sussex, Delaware, United States) was founded as a Delaware C-corp according to Articles of Incorporation made effective New Years' Day 2023 (2023/01/01, 05:00 EST). Arowor Corp. was chartered and held its Initial Shareholders Meeting with Corporate Bylaws established in January 2023. Aron Workman was elected Chairman and CEO at the Initial Shareholders Meeting. Mr. Workman is a biotechnologist and professional chairman with 13 years' experience running the stealth biotechnology R&D engine AXOXY Laboratories LLC (Gainesville, Florida, United States). Mr. Workman published a technical manuscript on superoxide dismutase molecular videography in November 2022. Mr. Workman resolved the 7.5 Year Patent Maintenance Fee for US Patent 8,916,373 in December 2022. Arowor Corp. made an investor presentation (pitch deck) and sent the presentation to less than one dozen venture capital firm agents, currently without investment. A small round was planted but failed due to exigency and perpetration by United States seed firms. There are ongoing efforts to raise a more fruitful round or pivot direct to Series A. Arowor Corp. launched its public website, YouTube, Twitter, and LinkedIn in January 2023. Open-source intelligence bulletins have been made available at the Arowor Corp. LinkedIn: · State of Florida Targeted by Nuclear Strike Simulations: Florida Draws Nuclear Heat as the Peninsular Warfare Capital of the World · AveXis' Zolgensma FDA Approval Conspiracy: Data Integrity and the Zolgensma FDA Approval Counter-Intelligence Conspiracy at AveXis, Inc. Arowor Corp. has successfully acquired and is closing multiple more microacquisitions across biotechnology and biopharmaceutical discovery and development. Arowor Corp. now owns or controls, either directly or indirectly through Mr. Aron Workman, Chairman, the following incorporated firms: DALTON COMP CENT SCIS LLC (Florida: L20000036599); CURE ALS1 LLC (Florida: L20000036654); AXOXY LABORATORIES LLC (Florida: L10000058137). Arowor Corp. now owns or controls, either directly or indirectly through Mr. Aron Workman, Chairman, the following unincorporated firms or projects: ATG BIOINFORMATICS; MOLECULAR.BIO; NEUROBIO; BIOPENTEL; AAOAA; INTELLISYS. Arowor Corp. has retired supercomputer KERATIN and is in the process of designing and procuring its next supercomputer: CARISSA. Arowor Corp. is actively developing and implementing biotechnology suites including the following platforms: MPM; HPC; SODA; SSRNA; QAI. Arowor Corp. is actively developing its computational suites, most notably Project VESUVIUS and the VESUVIUS Daemon. Arowor Corp. is actively developing biopharmaceuticals including the following drug candidates: H10N; RDP1; AO10; HSP1; CHP1; MYV1; GTXN; INSX; ARSX. Please contact Aron Workman, CEO, regarding serious interest in potential advisement, investment, or partnership. Aron Workman
AveXis Frequently Asked Questions (FAQ)
When was AveXis founded?
AveXis was founded in 2012.
Where is AveXis's headquarters?
AveXis's headquarters is located at 2275 Half Day Road, Deerfield.
What is AveXis's latest funding round?
AveXis's latest funding round is Acq - P2P.
How much did AveXis raise?
AveXis raised a total of $75M.
Who are the investors of AveXis?
Investors of AveXis include Novartis, Roche Venture Fund, Deerfield Management, JDH Investment Management, RA Capital Management and 13 more.
Who are AveXis's competitors?
Competitors of AveXis include CODA Biotherapeutics and 1 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare AveXis to Competitors
Evive Biotech is an integrated biotech company developing therapeutic biologics. Products under development are mainly aimed at unsolved medical problems, such as oncology, inflammation, and autoimmune diseases. The company was formerly known as Generon Biomed, Inc. and changed its name to Evive Biotech in June 2020. The company was founded in 2004 and is based in Singapore, Singapore.
StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies. The company is building a proprietary therapeutic pipeline focused on rare diseases.
Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers.
AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich's Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure.
Neurogene develops genetic medicines for patients and families affected by rare neurological diseases. It utilizes an adeno-associated virus (AAV) to deliver a healthy copy of a gene to people with a defect in the disease-causing gene. It was founded in 2018 and is based in New York, New York.
Redpin Therapeutics is a preclinical-stage gene therapy company. The company develops therapies that leverage ion channels as neuromodulation tools to selectively either activate or silence disease-causing neurons to regulate only dysfunctional neurons, while leaving normal functioning cells alone, enabling physicians to achieve targeted cell activation or inhibition to selectively stimulate or inhibit dysfunctional neuronal circuits implicated in a given disease. The company was founded in 2017 and is based in New York, New York. In November 2022, Redpin Therapeutics was acquired by Kriya Therapeutics. The terms of the transaction were not disclosed.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
